Differential signature of the centrosomal MARK4 isoforms in glioma

Ivana Magnani, Chiara Novielli, Laura Fontana, Silvia Tabano, Davide Rovina, Ramona F. Moroni, Dario Bauer, Stefania Mazzoleni, Elisa A. Colombo, Gabriella Tedeschi, Laura Monti, Giovanni Porta, Silvano Bosari, Carolina Frassoni, Rossella Galli, Lorenzo Bello, Lidia Larizza

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: MAP/microtubule affinity-regulating kinase 4 (MARK4) is a serine-threonine kinase expressed in two spliced isoforms, MARK4L and MARK4S, of which MARK4L is a candidate for a role in neoplastic transformation. Methods: We performed mutation analysis to identify sequence alterations possibly affecting MARK4 expression. We then investigated the MARK4L and MARK4S expression profile in 21 glioma cell lines and 36 tissues of different malignancy grades, glioblastoma-derived cancer stem cells (GBM CSCs) and mouse neural stem cells (NSCs) by real-time PCR, immunoblotting and immunohistochemistry. We also analyzed the sub-cellular localisation of MARK4 isoforms in glioma and normal cell lines by immunofluorescence. Results: Mutation analysis rules out sequence variations as the cause of the altered MARK4 expression in glioma. Expression profiling confirms that MARK4L is the predominant isoform, whereas MARK4S levels are significantly decreased in comparison and show an inverse correlation with tumour grade. A high MARK4L/MARK4S ratio also characterizes undifferentiated cells, such as GBM CSCs and NSCs. Accordingly, only MARK4L is expressed in brain neurogenic regions. Moreover, while both MARK4 isoforms are localised to the centrosome and midbody in glioma and normal cells, the L isoform exhibits an additional nucleolar localisation in tumour cells. Conclusions: The observed switch towards MARK4L suggests that the balance between the MARK4 isoforms is carefully guarded during neural differentiation but may be subverted in gliomagenesis. Moreover, the MARK4L nucleolar localisation in tumour cells features this MARK4 isoform as a nucleolus-associated tumour marker.

Original languageEnglish
Pages (from-to)319-338
Number of pages20
JournalAnalytical Cellular Pathology
Volume34
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Glioma
Microtubules
Protein Isoforms
Phosphotransferases
Neural Stem Cells
Neoplastic Stem Cells
Glioblastoma
Neoplasms
Cell Line
Centrosome
Mutation
Protein-Serine-Threonine Kinases
Tumor Biomarkers
Immunoblotting
Fluorescent Antibody Technique
Real-Time Polymerase Chain Reaction
Immunohistochemistry
Brain

Keywords

  • alternative splicing
  • glioma
  • MARK4 kinase
  • neural/cancer stem cells
  • nucleolus

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pathology and Forensic Medicine
  • Cell Biology
  • Medicine(all)

Cite this

Magnani, I., Novielli, C., Fontana, L., Tabano, S., Rovina, D., Moroni, R. F., ... Larizza, L. (2011). Differential signature of the centrosomal MARK4 isoforms in glioma. Analytical Cellular Pathology, 34(6), 319-338. https://doi.org/10.3233/ACP-2011-0031

Differential signature of the centrosomal MARK4 isoforms in glioma. / Magnani, Ivana; Novielli, Chiara; Fontana, Laura; Tabano, Silvia; Rovina, Davide; Moroni, Ramona F.; Bauer, Dario; Mazzoleni, Stefania; Colombo, Elisa A.; Tedeschi, Gabriella; Monti, Laura; Porta, Giovanni; Bosari, Silvano; Frassoni, Carolina; Galli, Rossella; Bello, Lorenzo; Larizza, Lidia.

In: Analytical Cellular Pathology, Vol. 34, No. 6, 2011, p. 319-338.

Research output: Contribution to journalArticle

Magnani, I, Novielli, C, Fontana, L, Tabano, S, Rovina, D, Moroni, RF, Bauer, D, Mazzoleni, S, Colombo, EA, Tedeschi, G, Monti, L, Porta, G, Bosari, S, Frassoni, C, Galli, R, Bello, L & Larizza, L 2011, 'Differential signature of the centrosomal MARK4 isoforms in glioma', Analytical Cellular Pathology, vol. 34, no. 6, pp. 319-338. https://doi.org/10.3233/ACP-2011-0031
Magnani I, Novielli C, Fontana L, Tabano S, Rovina D, Moroni RF et al. Differential signature of the centrosomal MARK4 isoforms in glioma. Analytical Cellular Pathology. 2011;34(6):319-338. https://doi.org/10.3233/ACP-2011-0031
Magnani, Ivana ; Novielli, Chiara ; Fontana, Laura ; Tabano, Silvia ; Rovina, Davide ; Moroni, Ramona F. ; Bauer, Dario ; Mazzoleni, Stefania ; Colombo, Elisa A. ; Tedeschi, Gabriella ; Monti, Laura ; Porta, Giovanni ; Bosari, Silvano ; Frassoni, Carolina ; Galli, Rossella ; Bello, Lorenzo ; Larizza, Lidia. / Differential signature of the centrosomal MARK4 isoforms in glioma. In: Analytical Cellular Pathology. 2011 ; Vol. 34, No. 6. pp. 319-338.
@article{e1320698b50f48b6b7a761f7c5e864ed,
title = "Differential signature of the centrosomal MARK4 isoforms in glioma",
abstract = "Background: MAP/microtubule affinity-regulating kinase 4 (MARK4) is a serine-threonine kinase expressed in two spliced isoforms, MARK4L and MARK4S, of which MARK4L is a candidate for a role in neoplastic transformation. Methods: We performed mutation analysis to identify sequence alterations possibly affecting MARK4 expression. We then investigated the MARK4L and MARK4S expression profile in 21 glioma cell lines and 36 tissues of different malignancy grades, glioblastoma-derived cancer stem cells (GBM CSCs) and mouse neural stem cells (NSCs) by real-time PCR, immunoblotting and immunohistochemistry. We also analyzed the sub-cellular localisation of MARK4 isoforms in glioma and normal cell lines by immunofluorescence. Results: Mutation analysis rules out sequence variations as the cause of the altered MARK4 expression in glioma. Expression profiling confirms that MARK4L is the predominant isoform, whereas MARK4S levels are significantly decreased in comparison and show an inverse correlation with tumour grade. A high MARK4L/MARK4S ratio also characterizes undifferentiated cells, such as GBM CSCs and NSCs. Accordingly, only MARK4L is expressed in brain neurogenic regions. Moreover, while both MARK4 isoforms are localised to the centrosome and midbody in glioma and normal cells, the L isoform exhibits an additional nucleolar localisation in tumour cells. Conclusions: The observed switch towards MARK4L suggests that the balance between the MARK4 isoforms is carefully guarded during neural differentiation but may be subverted in gliomagenesis. Moreover, the MARK4L nucleolar localisation in tumour cells features this MARK4 isoform as a nucleolus-associated tumour marker.",
keywords = "alternative splicing, glioma, MARK4 kinase, neural/cancer stem cells, nucleolus",
author = "Ivana Magnani and Chiara Novielli and Laura Fontana and Silvia Tabano and Davide Rovina and Moroni, {Ramona F.} and Dario Bauer and Stefania Mazzoleni and Colombo, {Elisa A.} and Gabriella Tedeschi and Laura Monti and Giovanni Porta and Silvano Bosari and Carolina Frassoni and Rossella Galli and Lorenzo Bello and Lidia Larizza",
year = "2011",
doi = "10.3233/ACP-2011-0031",
language = "English",
volume = "34",
pages = "319--338",
journal = "Analytical Cellular Pathology",
issn = "2210-7177",
publisher = "IOS Press",
number = "6",

}

TY - JOUR

T1 - Differential signature of the centrosomal MARK4 isoforms in glioma

AU - Magnani, Ivana

AU - Novielli, Chiara

AU - Fontana, Laura

AU - Tabano, Silvia

AU - Rovina, Davide

AU - Moroni, Ramona F.

AU - Bauer, Dario

AU - Mazzoleni, Stefania

AU - Colombo, Elisa A.

AU - Tedeschi, Gabriella

AU - Monti, Laura

AU - Porta, Giovanni

AU - Bosari, Silvano

AU - Frassoni, Carolina

AU - Galli, Rossella

AU - Bello, Lorenzo

AU - Larizza, Lidia

PY - 2011

Y1 - 2011

N2 - Background: MAP/microtubule affinity-regulating kinase 4 (MARK4) is a serine-threonine kinase expressed in two spliced isoforms, MARK4L and MARK4S, of which MARK4L is a candidate for a role in neoplastic transformation. Methods: We performed mutation analysis to identify sequence alterations possibly affecting MARK4 expression. We then investigated the MARK4L and MARK4S expression profile in 21 glioma cell lines and 36 tissues of different malignancy grades, glioblastoma-derived cancer stem cells (GBM CSCs) and mouse neural stem cells (NSCs) by real-time PCR, immunoblotting and immunohistochemistry. We also analyzed the sub-cellular localisation of MARK4 isoforms in glioma and normal cell lines by immunofluorescence. Results: Mutation analysis rules out sequence variations as the cause of the altered MARK4 expression in glioma. Expression profiling confirms that MARK4L is the predominant isoform, whereas MARK4S levels are significantly decreased in comparison and show an inverse correlation with tumour grade. A high MARK4L/MARK4S ratio also characterizes undifferentiated cells, such as GBM CSCs and NSCs. Accordingly, only MARK4L is expressed in brain neurogenic regions. Moreover, while both MARK4 isoforms are localised to the centrosome and midbody in glioma and normal cells, the L isoform exhibits an additional nucleolar localisation in tumour cells. Conclusions: The observed switch towards MARK4L suggests that the balance between the MARK4 isoforms is carefully guarded during neural differentiation but may be subverted in gliomagenesis. Moreover, the MARK4L nucleolar localisation in tumour cells features this MARK4 isoform as a nucleolus-associated tumour marker.

AB - Background: MAP/microtubule affinity-regulating kinase 4 (MARK4) is a serine-threonine kinase expressed in two spliced isoforms, MARK4L and MARK4S, of which MARK4L is a candidate for a role in neoplastic transformation. Methods: We performed mutation analysis to identify sequence alterations possibly affecting MARK4 expression. We then investigated the MARK4L and MARK4S expression profile in 21 glioma cell lines and 36 tissues of different malignancy grades, glioblastoma-derived cancer stem cells (GBM CSCs) and mouse neural stem cells (NSCs) by real-time PCR, immunoblotting and immunohistochemistry. We also analyzed the sub-cellular localisation of MARK4 isoforms in glioma and normal cell lines by immunofluorescence. Results: Mutation analysis rules out sequence variations as the cause of the altered MARK4 expression in glioma. Expression profiling confirms that MARK4L is the predominant isoform, whereas MARK4S levels are significantly decreased in comparison and show an inverse correlation with tumour grade. A high MARK4L/MARK4S ratio also characterizes undifferentiated cells, such as GBM CSCs and NSCs. Accordingly, only MARK4L is expressed in brain neurogenic regions. Moreover, while both MARK4 isoforms are localised to the centrosome and midbody in glioma and normal cells, the L isoform exhibits an additional nucleolar localisation in tumour cells. Conclusions: The observed switch towards MARK4L suggests that the balance between the MARK4 isoforms is carefully guarded during neural differentiation but may be subverted in gliomagenesis. Moreover, the MARK4L nucleolar localisation in tumour cells features this MARK4 isoform as a nucleolus-associated tumour marker.

KW - alternative splicing

KW - glioma

KW - MARK4 kinase

KW - neural/cancer stem cells

KW - nucleolus

UR - http://www.scopus.com/inward/record.url?scp=84864591281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864591281&partnerID=8YFLogxK

U2 - 10.3233/ACP-2011-0031

DO - 10.3233/ACP-2011-0031

M3 - Article

VL - 34

SP - 319

EP - 338

JO - Analytical Cellular Pathology

JF - Analytical Cellular Pathology

SN - 2210-7177

IS - 6

ER -